Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Clinical trial NCT01498484 · COMPLETED

Trial details

NCT number: NCT01498484
Sponsor: Atara Biotherapeutics
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

EBV-induced Lymphomas EBV-associated Malignancies Transplant Patients With EBV Viremia at High Risk for Developing a Recurrent EBV Lymphoma

Start date: 2011-12-01
Primary completion: 2019-07-01
Enrollment: 87

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.